Nasdaq · Common stock
IRulya Therapeutics (IRLA)
$31.38 −$1.70 (−5.14%)
- Day’s range
- $30.32–$35.20
- Volume
- 53,161
IRLA price history
IRLA closed at $31.38 on Oct. 26, 2026. Over the past year, its daily close ranged from $27.87 on Oct. 13, 2026 to $40.27 on Oct. 20, 2026.
Data table: IRLA daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $31.38 |
| Oct. 23, 2026 | $33.08 |
| Oct. 22, 2026 | $32.83 |
| Oct. 21, 2026 | $34.68 |
| Oct. 20, 2026 | $40.27 |
| Oct. 19, 2026 | $34.45 |
| Oct. 16, 2026 | $32.03 |
| Oct. 15, 2026 | $33.23 |
| Oct. 14, 2026 | $30.00 |
| Oct. 13, 2026 | $27.87 |
| Oct. 12, 2026 | $32.40 |
Key figures
- 52-week range
- —
- Average daily volume
- 99,342Past 3 months
- Market value
- $31.9M
- Dividend yield
- —
- From 52-week high
- —
Price change
- 1 month
- —
- 3 months
- —
- Year to date
- —
- 1 year
- —
What Wall Street says about IRLA
No Wall Street firm has published a rating or price-target change on IRLA in the past 90 days.
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About IRulya Therapeutics Inc. Common Stock
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
- Headquarters
- South San Francisco, Calif.
- Employees
- 38
- Listed
- May 9, 2019
- Sector
- Health care
- Industry
- Biological products, (no diagnostic substances)
In WallStreetDigest editions
No WallStreetDigest article about IRLA is on the site yet.